Chordia Therapeutics announced its AMED funding selection on 30 September, and its share price rose ¥2 from the previous day to ¥69. The high reached ¥86, while trading volume expanded sharply from the previous day.
Chordia Therapeutics disclosed its AMED funding selection on 30 September. As a result, its share price recently rose ¥2 from the previous day to ¥69, with buying pushing the high to ¥86.
In its financial results, the company reportedly recorded no revenue and posted an operating loss of ¥1.07 billion for the cumulative period of the fiscal year ending July 2026. Cash and deposits stood at ¥2.506 billion. The company is also working to secure future funding through the issuance of stock acquisition rights.
The AMED funding selection relates to drug discovery and development in the oncology field, centered on RoGocekiB (CTX-712), with attention focused on developments including the move to an expanded cohort in the United States and the reacquisition of rights. Securing development funding and progress in the pipeline may be key areas of focus going forward.